Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Tesamorelin and ipamorelin blend: what is in it and does it work?

Tesamorelin is FDA approved as Egrifta; ipamorelin has no compounding basis. Mixed together they are untested and cannot be compounded.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

At a glance

The tesamorelin and ipamorelin blend pairs an FDA approved GHRH analog (Egrifta) with an unapproved ghrelin receptor agonist to raise growth hormone. No study has tested the combination. Tesamorelin alone has a lawful prescription path as Egrifta WR; the blend does not, because neither ingredient can be lawfully compounded.

Evidence: Blend never studiedRegulatory: No federal basis to compoundWADA: WADA prohibited
What is in it
Tesamorelin, Ipamorelin
Evidence for the combination
No published study of the blend. Each ingredient is graded on its own.
Legal status
No federal basis to compound, set by Ipamorelin.
Tested athletes
Prohibited: Tesamorelin and Ipamorelin are on the WADA list.

What is in the tesamorelin and ipamorelin blend?

Tesamorelin and ipamorelin contains Tesamorelin and Ipamorelin. Products sold under this name combine the two peptides in one vial or as a two-vial kit, in amounts and ratios that vary by seller. The tesamorelin in these products is not the FDA approved Egrifta product and is not made to its standard. PeptideAgent does not name or link sellers.

Also searched as: Tesamorelin ipamorelin blend; Tesamorelin/ipamorelin; Tesamorelin and ipamorelin.

Ingredients in the tesamorelin and ipamorelin blend, with each peptide's own evidence grade, FDA status, and WADA status
IngredientWhy it is in the mixStatus (alone)
TesamorelinSold as the GHRH component; the only ingredient with FDA approval and large randomized trials.
Evidence: Human RCT evidence
Regulatory: FDA approved
WADA: WADA prohibited
IpamorelinAdded to trigger growth hormone pulses through the ghrelin receptor, based on animal studies and one small human pharmacology study.
Evidence: Human RCT evidence
Regulatory: Nomination withdrawn
WADA: WADA prohibited

Grades and statuses come from each peptide's own record and update with it. Grades follow the methodology.

Why are these peptides combined in the tesamorelin and ipamorelin blend?

The idea is the same as other GHRH and ghrelin mimetic pairings: stimulate growth hormone through both of its release pathways at once. A 1990 study in 18 healthy men found that GHRH and a synthetic ghrelin receptor hexapeptide given together released more growth hormone than either alone.

Tesamorelin brings the strongest evidence of any GHRH analog. In two phase 3 trials with 806 adults with HIV and excess abdominal fat, daily tesamorelin reduced visceral fat by about 15 percent relative to placebo over 26 weeks, and a later NIH funded trial found reduced liver fat. Sellers borrow that record for the blend, but it was earned by tesamorelin alone, in a specific population. [1] [3] [5]

Has the tesamorelin and ipamorelin blend been studied?

No published study has tested tesamorelin with ipamorelin in humans or animals.

The tesamorelin trials enrolled adults with HIV associated lipodystrophy and measured visceral fat by imaging; visceral fat returned toward baseline after treatment stopped. They did not test people without HIV, muscle growth, or combinations with other peptides.

One small human pharmacology study showed a single IV infusion of ipamorelin releases growth hormone in healthy men; its only randomized trial (postoperative ileus) was negative; no human trial measured body composition or muscle. Adding it to tesamorelin has no measured upside and adds an unapproved ingredient. [3] [4] [12]

What each ingredient has shown alone

  • Tesamorelin (human RCT evidence). FDA approved lab-made growth hormone releasing hormone (Egrifta, 2010) that cuts deep belly fat about 15% in HIV lipodystrophy and cut liver fat in a trial.
  • Ipamorelin (human RCT evidence). Growth hormone releaser acting on the hunger hormone (ghrelin) receptor; its one randomized placebo controlled trial, after bowel surgery, found no benefit.

Tesamorelin and ipamorelin results and before and after claims

Measured tesamorelin before and after results come from trials: visceral fat inside the abdomen fell, fat under the skin of the abdomen did not change, and patients rated their belly appearance as improved. A 12 month trial in people with HIV and fatty liver found a lower liver fat fraction. These are real, modest, population-specific results.

No study shows what the blend does. Photos of people using it cannot separate tesamorelin from ipamorelin, diet, training, and other drugs. The tesamorelin trials were not designed to show muscle growth, and none measured it as an outcome.

A 2026 review of growth hormone axis peptides used outside medical care describes how stacking in unregulated supply leaves claimed body recomposition benefits uncertain. [3] [5] [6]

What are the side effects of the tesamorelin and ipamorelin blend?

Tesamorelin's label lists joint pain, injection site reactions, swelling, muscle pain, tingling or numbness, nausea, and rash, and warns about glucose intolerance, raised IGF-1, hypersensitivity, and fluid retention. It is contraindicated in pregnancy, in active malignancy, and in people whose pituitary axis has been disrupted.

Ipamorelin adds an ingredient with no human safety data at the amounts sold, and FDA cited immunogenicity risk from impurities when it placed ipamorelin in Category 2. Stimulating growth hormone by two routes could add up glucose, fluid, and IGF-1 effects; this has not been studied.

A blend made outside the approved product is not manufactured or tested to the approved product's standard, so its tesamorelin content is also unverified. [6] [7] [8]

Reported for each ingredient

From each peptide's record. These were reported for the peptide alone, not for the blend. Absence of data is not evidence of safety.

Side effects reported for each ingredient of the tesamorelin and ipamorelin blend
IngredientReported side effects and safety notes
Tesamorelin
  • Arthralgia (about 13%)
  • Injection site reactions (redness, itching, pain, irritation, bruising) in 25% versus 14% on placebo over 26 weeks
  • Peripheral edema, myalgia, pain in extremities
  • Paresthesia and hypoesthesia
Ipamorelin
  • No safety signal versus placebo in the 7 day intravenous ileus trial (adverse events 87.5% versus 94.8%, mostly surgical)
  • Injection site reactions, headache, flushing, and lightheadedness reported anecdotally
  • Increased appetite (ghrelin receptor effect) reported anecdotally
  • FDA cited immunogenicity risk from aggregation and impurities and limited safety data by the routes used in compounding when it placed ipamorelin in Category 2
Regulatory: No federal basis to compoundWADA: WADA prohibited

A blend inherits the strictest status among its ingredients, because a mixed product is only as lawful as its least lawful component. For the tesamorelin and ipamorelin blend that is Ipamorelin: no federal basis to compound. At least one ingredient is not FDA approved and not on the 503A bulks list, so a licensed pharmacy has no federal basis to compound the mix.

Why blends like this are sold as research chemicals

A drug for human use in the United States has to be FDA approved or lawfully compounded by a licensed pharmacy for a named patient under a prescription. This blend can be neither, so vials sold under its name carry labels such as “for research use only” or “not for human consumption”. That label does not make a product lawful to inject, and it means no one has checked the vial for identity, purity, sterility, or amount. [10]

WADA status

Tesamorelin and Ipamorelin are prohibited at all times on the WADA list, so any product containing them is prohibited for athletes subject to anti-doping testing.

State rules: peptide laws by state. All FDA actions: regulatory tracker.

What does the tesamorelin and ipamorelin blend cost, and what can a provider lawfully offer?

Tesamorelin is the only peptide in this blend with a lawful path. Egrifta WR is FDA approved and available by prescription. Egrifta WR (a biologic under BLA 022505) is the only lawful product, and biologics fall outside 503A, so tesamorelin cannot be compounded. Use for fat loss in people without HIV is off-label.

Ipamorelin has no federal basis to be compounded: its 503A nominations were withdrawn, it is not on the 503A bulks list, and it is not a component of an approved drug. A vial that contains ipamorelin has no federal basis to be compounded, so the blend has no lawful price.

What a prescriber can lawfully offer is tesamorelin by itself, as the approved product Egrifta WR. The tesamorelin cost page lists published prices by channel. [7] [8] [9] [10] [13]

What's actually offered, and what that means for you

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [14] [15] [16]

Being offered does not change the legal status of the tesamorelin and ipamorelin blend. Ipamorelin is not FDA approved and not on the 503A bulks list, so a pharmacy has no federal basis to compound the mix. [8] [10]

Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [8] [9] [14] [17] [18] [19]

What that means for you

  • A pharmacy that compounds the tesamorelin and ipamorelin blend is taking a regulatory risk: it has no federal basis to do so, and FDA has sent warning letters to compounders for the same thing. [14] [17]
  • No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [9]
  • State boards can act. On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [20]
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [21] [22]
  • Identity, purity, sterility, and dose accuracy can vary from batch to batch. [8]
  • Insurance rarely covers it, so you usually pay cash.
  • For tested athletes, the tesamorelin and ipamorelin blend contains at least one ingredient that is prohibited under the WADA Prohibited List. [11]

If you're going ahead anyway

These steps lower some risks. They do not make the product safe, and they do not give a pharmacy a federal basis to compound the tesamorelin and ipamorelin blend, with or without a prescription. [10]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [23] [24] [25]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [16] [25] [26]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [9] [27] [28] [29] [30] [31]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [9]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [23]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [16]
  • Pharmacy: Is this made for me on a prescription written in my name? [26]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [16] [25]
  • Prescriber: What is the legal basis for a pharmacy to compound the tesamorelin and ipamorelin blend? Is it FDA approved or on the 503A bulks list? [9] [10]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [16]

In Mississippi, there is no legitimate prescriber route for a peptide that is not FDA approved: licensed providers may not prescribe or supply one, and a patient who gets one on their own carries the risk alone. [20]

The approved option is Egrifta WR, by prescription. See Egrifta WR cost by channel.

Compare the ingredients

Blends that share an ingredient

  • CJC-1295 and ipamorelin: CJC-1295 and ipamorelin pair a GHRH analog with a ghrelin mimetic to raise growth hormone. The pair is untested, and neither peptide has a lawful path.
  • Sermorelin and ipamorelin: Sermorelin and ipamorelin pair a formerly approved GHRH fragment with a ghrelin mimetic. The pair is untested, and ipamorelin has no compounding basis.

Frequently asked questions

What is the tesamorelin and ipamorelin blend?

It is a mix of tesamorelin, an FDA approved GHRH analog, and ipamorelin, an unapproved ghrelin receptor agonist, sold to raise growth hormone. The combination has never been tested. [2] [3]

Is the tesamorelin and ipamorelin blend FDA approved?

No. Tesamorelin alone is approved as Egrifta to reduce excess abdominal fat in adults with HIV lipodystrophy. No product combining it with ipamorelin is approved, and ipamorelin has no federal basis to be compounded. [7] [10]

Does the blend work better than tesamorelin alone?

There is no evidence that it does. The synergy idea comes from single-dose hormone studies of other molecules, ipamorelin's one randomized human trial was negative, and no study compared the blend with tesamorelin. [1] [3] [4]

Does tesamorelin help build muscle?

Its phase 3 trials measured visceral fat, not muscle size or strength, and were not designed to show muscle growth. Claims that tesamorelin or the blend builds muscle are not supported by trial data. [3]

Is the tesamorelin and ipamorelin blend legal?

The blend is not. Tesamorelin can be prescribed as Egrifta WR, but as a biologic it is not eligible for the 503A or 503B compounding exemptions, and ipamorelin has no federal basis to be compounded, so a product containing both cannot be compounded. [7] [9] [10] [13]

What are the side effects of the tesamorelin and ipamorelin blend?

The blend has no safety study. Tesamorelin's label lists joint pain, injection site reactions, swelling, and glucose intolerance, and ipamorelin adds an unapproved ingredient that FDA flagged for immunogenicity risk. [7] [8]

Is the blend allowed for tested athletes?

No. Tesamorelin and ipamorelin are both named in WADA section S2 and are prohibited at all times. [11]

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Bowers CY et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990PubMed 2108187, 1990
  2. [2]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998PubMed 9849822, 1998
  3. [3]Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010PubMed 20554713, 2010
  4. [4]Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014PubMed 25331030, 2014
  5. [5]Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019PubMed 31611038, 2019
  6. [6]Dominikowski A et al. The emerging landscape of performance-enhancing peptides modulating the GH-IGF-1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026PubMed 42395176, 2026
  7. [7]FDA prescribing information for Egrifta SV (tesamorelin for injection), via DailyMedFDA, 2025
  8. [8]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
  9. [9]FDA: Compounding and the FDA, questions and answers (including risks of compounded drugs and enforcement policy for nominated bulk substances)FDA, 2026
  10. [10]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 30). Tesamorelin and ipamorelin blend: what is in it and does it work?. https://peptideagent.ai/blends/tesamorelin-ipamorelin
HTML link
<a href="https://peptideagent.ai/blends/tesamorelin-ipamorelin">Tesamorelin and ipamorelin blend: what is in it and does it work?</a>, PeptideAgent, updated September 30, 2026.